Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients-Reference-Cited by-同舟云学术

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients

Published:2021-02-06 Issue:3 Volume:8 Page:548-557
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann. Clin. Transl. Neurol.

Author:

Pane Marika¹²^ORCID,Coratti Giorgia¹²^ORCID,Sansone Valeria A.³^ORCID,Messina Sonia⁴^ORCID,Catteruccia Michela⁵^ORCID,Bruno Claudio⁶,Sframeli Maria⁴,Albamonte Emilio³,Pedemonte Marina⁶,D’Amico Adele⁵,Bravetti Chiara²,Berti Beatrice²,Palermo Concetta²,Leone Daniela²,Brigati Giorgia⁶,Tacchetti Paola⁶,Salmin Francesca³,De Sanctis Roberto²,Lucibello Simona¹²,Pera Maria Carmela¹²,Piastra Marco⁷,Genovese Orazio⁷,Bertini Enrico⁵^ORCID,Vita Gianluca⁴,Tiziano Francesco Danilo⁸,Mercuri Eugenio¹²^ORCID,

Affiliation:

1. Paediatric Neurology Catholic University Rome Italy

2. Centro Clinico Nemo Fondazione Policlinico Universitario Agostino Gemelli IRCSS Rome Italy

3. Neurorehabilitation Unit Centro Clinico Nemo Niguarda HospitalUniversity of Milan Milano Italy

4. Department of Clinical and Experimental Medicine University of Messina and Centro Clinico Nemo Messina Italy

5. Unit of Neuromuscular and Neurodegenerative Disorders Bambino Gesù Children's Hospital IRCCS Rome Italy

6. Center of Myology and Neurodegenerative Disorders Istituto Giannina Gaslini Genoa Italy

7. Pediatric Intensive Care Unit Catholic University and Policlinico GemelliFondazione Policlinico Universitario Agostino Gemelli IRCSS Rome Italy

8. Institute of Genomic Medicine Catholic University and Policlinico GemelliFondazione Policlinico Universitario Agostino Gemelli IRCSS Rome Italy

Funder

Fondazione Telethon

Publisher

Wiley

Subject

Clinical Neurology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51276

Reference16 articles.

1. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen

2. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1

3. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany

4. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1

5. Nusinersen in type 1 spinal muscular atrophy: Twelve‐month real‐world data

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study;Archives of Disease in Childhood;2024-01-30

2. Gene-Based Therapy for the Treatment of Spinal Muscular Atrophy Types 1 and 2 : A Systematic Review and Meta-Analysis;2023-12-07

3. Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type;Archives de Pédiatrie;2023-12

4. Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan;International Journal of Neuroscience;2023-09-07

5. Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation;Arquivos de Neuro-Psiquiatria;2023-09